EDIL3 Knockout HGC-27 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal population with targeted disruption of the EDIL3 gene in the HGC-27 human gastric carcinoma cell line. This polyclonal format yields a heterogeneous mixture of loss-of-function mutations, reducing clonal selection bias and enabling robust functional genomics experiments. The knockout abrogates EDIL3 protein expression, offering a versatile model to study loss of this secreted factor in a relevant cancer background.
The HGC-27 cell line is an undifferentiated gastric adenocarcinoma derived from a lymph node metastasis, extensively used as a model of invasive gastric cancer. It displays high migratory and invasive potential in vitro, for instance in wound healing and transwell assays, mirroring the aggressive behavior of metastatic carcinoma. Endogenous EDIL3 expression in HGC-27 contributes to its malignant properties, rendering this knockout cell pool particularly suited for dissecting EDIL3-dependent mechanisms in gastric cancer progression and metastasis.
EDIL3 encodes the secreted glycoprotein Del-1, which acts as a ligand for integrins ??v??3, ??v??5, and LFA-1. Engagement of these receptors triggers activation of FAK and Src, leading to phosphorylation of AKT and ERK1/2, and transcriptional regulation of NF-??B and MMPs. Upstream, EDIL3 is controlled by HIF1A under hypoxia and by inflammatory cytokines TNF-?? and IL-1??. Through these pathways, Del-1 promotes cell adhesion, migration, angiogenesis, and immune modulation.
In gastric carcinoma, elevated EDIL3 correlates with increased tumor growth and metastasis, mediated by FAK/PI3K/AKT signaling and remodeling of the tumor microenvironment. Knocking out EDIL3 in HGC-27 cells permits investigation of tumor cell reliance on autocrine/paracrine Del-1 and the elucidation of compensatory signaling networks. This model is valuable for studying alterations in cell motility, endothelial tube formation, and in vivo tumorigenesis, as well as integrin-mediated outside-in signaling and inflammatory crosstalk.
The EDIL3 knockout polyclonal cells support a range of applications, including mechanistic studies of integrin signaling, screens for angiogenesis modulators, and preclinical drug testing targeting the EDIL3 pathway. Key experiments involve assessing changes in cell behavior and signaling upon loss of EDIL3. Typical assays employ Western blotting, RT-qPCR, transwell migration/invasion, cell adhesion, tube formation, and xenograft tumor models. For further information or to inquire about custom applications, please contact Ascent Research.
